Montelukast API Market Overview
The Global Montelukast API Market is estimated to be valued at USD 1,430,215.2 thousand by 2023 and is expected to register a CAGR of 3.38% during the forecast period.The asthma segment is expected to lead the market and register a substantial CAGR to reach USD 700,730.7 thousand by the end of 2023 owing to the rising prevalence of asthma. Montelukast API is much in demand across the globe for the treatment of asthma. However, the allergic rhinitis segment is projected to exhibit the highest CAGR of 3.11% from 2018 to 2023. The rising rate of allergic rhinitis cases is driving the growth of the segment.
The global Montelukast API Market is growing at the fastest pace, witnessing increasing demand and the expanding healthcare sector. Montelukast API is referred as pharmaceutical molecules that form the core components of drugs & medicines, either singly or in combination. It is an orally available leukotriene receptor antagonist, which is widely used in the development and manufacturing of medicines used in the treatment of asthma, respiratory problems, hay fever, allergic rhinitis, and others.
North America accounted for the largest market share of 39.25% in 2017, and the regional market is projected to register a CAGR of 3.12% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.10% during the forecast period from 2018 to 2023.
Montelukast API Market Segmentation
The global montelukast API market has been segmented on the basis of applications, and region. On the basis of the applications, the market has been divided into asthma, allergic rhinitis, bronchospasm, urticarial and others. The asthma segment held the majority market share in 2017. Allergic rhinitis segment is expected to be the fastest-growing, followed by the asthma segment. Rising prevalence of allergic rhinitis is driving the growth of the segment.
Montelukast API Market Regional Analysis
North America accounted for the largest market share of 39.25% in 2017, and the regional market is projected to register a CAGR of 3.12% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.10% during the forecast period from 2018 to 2023.
The European market is estimated to exceed USD 396,258 thousand by 2023. Increasing incidence of asthma, COPD, and allergies are driving the growth of the Montelukast API market in the region. The UK is the major contributor to the growth of the regional market, followed by France.
Montelukast API Market Players
- Glenmark (India),
- Vintage Pharmaceuticals Inc (US)
- Hikma Pharmaceuticals PLC (UK)
- Sandoz International GmbH (Germany)
- Hetero (India)
- Aurobindo Pharma (India)
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/montelukast-api-market-7886 About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]
Montelukast API Market: Information by Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Global Forecast till 2027Market HighlightsThe Global Montelukast API Market is estimated to be valued at USD 1,430,215.2 thousand by 2023 and is expected to register a CAGR of 3.38% during the forecast period.The asthma segment is expected to lead the market and register a substantial CAGR to reach USD 700,730.7 thousand by the end of 2023 owing to the rising prevalence of asthma.
Montelukast API is much in demand across the globe for the treatment of asthma.
The rising rate of allergic rhinitis cases is driving the growth of the segment.North America accounted for the largest market share of 39.25% in 2017, and the regional market is projected to register a CAGR of 3.12% during the forecast period.
The Chinese market is projected to exhibit the highest growth rate of 5.10% during the forecast period from 2018 to 2023.
Segment AnalysisThe global montelukast API market has been segmented on the basis of applications, and region.
On the basis of the applications, the market has been divided into asthma, allergic rhinitis, bronchospasm, urticarial and others.
Montelukast API Market OverviewAs per Market Research Future (MRFR) analysis, the global montelukast API market is expected to reach USD 1,430,215.2 thousand with a CAGR of 3.38% from 2018 to 2023 (forecast period).
The report is an exclusive research report that provides a comprehensive overview of the market.
It includes detailed information on key players operating in the market, with a focus on market revenue estimates, growth rate, and forecasts for the coming years.
The research report on the montelukast API industry offers a significant and in-depth study of market shares of players and dominant market segments for various regions around the globe.The global montelukast API market size is growing at the fastest pace, with increasing demand and an expanding healthcare sector.
It is used to avoid respiratory issues associated with exercise-induced bronchospasm.
Montelukast API Market Key PlayersThe prominent participants in the global montelukast API market are Merck Sharp & Dohme Corp (US), Dr. Reddy’s Laboratories Ltd (India), Mylan N.V. (US), Morepen Laboratories Ltd (India), Teva Pharmaceutical Industries Ltd (Israel), Glenmark (India), Vintage Pharmaceuticals Inc (US), Hikma Pharmaceuticals PLC (UK), Sandoz International GmbH (Germany), Hetero (India) and Aurobindo Pharma (India).Montelukast API Market DynamicsThe growing prevalence of asthma has significantly boosted the global market for montelukast API.
In-depth study of the Montelukast Intermediate Industry that helps to provide answers and relevant questions regarding the Emerging trends and Growth opportunities.
It helps identify each of the major growth barriers aside from identifying the trends in the Montelukast Intermediate market.Global montelukast intermediate market is expected to reach USD 8,715.3 thousand by 2026, growing at a CAGR of 4.71% during the forecast period, 2019–2026.Get Access to Report Sample: https://straitsresearch.com/report/montelukast-intermediate-market/request-sampleMajor Key players covered in this report:ORTIN LABORATORIES LIMITED (India), MANUS AKTTEVA (India), P.G.Shah & Co. (India), VIVAN Life Sciences (India), Arch Pharmalabs (India), Admiron Life Sciences Pvt Ltd (India), Zhejiang Tianyu Pharmaceutical Co. Ltd (China), and Actis Generics Pvt Ltd. (India).By Application, Asthma , Bronchospasm , Allergic Rhinitis , UrticariaBy End user, Pharmaceutical & Biotechnological Companies , Laboratories , OthersThe Montelukast Intermediate Market report offers an in-depth analysis of the Global Market and several important aspects related to it.
It provides its readers with great knowledge about current market dynamics, current market valuation, and past statistics as well.
This helps researchers in the study of the market’s performance so far and predicting the further performance for the forecasted period.
This part of the report has been studied keeping in mind the political, economic, social, technological, geographical, and cultural scenario of the Montelukast Intermediate Market.
These factors can be projected to have their individual effects on the market, or they can have interconnected impacts.
Montelukast Intermediate Market Size report offers insights into the leading market players and presents an assessment of their current market position.
Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M activities, and the latest R initiatives is also available in the reportThe report presents a detailed analysis of Montelukast Intermediate Market Size by providing readers with a comprehensive overview of the market’s historical trajectory.
The leading drivers and restraints affecting the global prostate cancer market are assessed in detail in the report.
The historical impact of these drivers and restraints is analyzed in context of the current impact of these factors and projections are made for the likely impact of these drivers and restraints over the forecast period.Major Key PlayersTo gain a substantially large competitive advantage, these players incorporate strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product launch.VIVAN Life Sciences, P.G.
Shah & Co., Manus Aktteva Biopharma LLP and Ortin Laboratories Limited.Market Segment AnalysisThe global Montelukast Intermediate market, by application, can be classified into three types, namely, asthma, allergic rhinitis, bronchospasm, and urticaria.Global Montelukast Intermediate Market, by ApplicationAsthmaAllergic RhinitisBronchospasmUrticariaChapters for This Montelukast Intermediate Market Size Study: -Chapter 1: to describe Global Montelukast Intermediate Market Size Introduction, product scope, market overview, market opportunities, market risk, market driving force;Chapter 2: to analyze the top manufacturers of Global Montelukast Intermediate Market Size, with sales, revenue, and price of Global Montelukast Intermediate Market Size.Chapter 3: to display the competitive situation among the top manufacturers, with sales, revenue and market share in Forecasted Time.Chapter 4: to show the Global Montelukast Intermediate Market Size by regions, with sales, revenue and market share of Global Montelukast Intermediate Market Size, for each region, during the forecast period.Chapter 5, 6, 7, 8 and 9: to analyze the key regions, with sales, revenue and market share by key countries in these regions;Chapter 10: to show the market by type and application, with sales market share and growth rate by type, application, Methodology, Analyst Introduction, Data Source By MRFRBrowse Full Report Page Enabled with complete Table of Content at https://www.marketresearchfuture.com/reports/montelukast-intermediate-market-7887Regional AnalysisGeographically, the global Montelukast Intermediate Market Size has been divided by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South AmericaAbout Market Research Future: MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.Contact:+1 646 845 9312 | Email: [email protected]
